Page 1 | Search Results | Cancer Research | American Association for Cancer Research

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Abstract 2250: STRO-002, an anti-FolRαADC, demonstrates immune-modulating properties and potentiates PD-L1 blockade

Millicent Embry, Sihong Zhou, Christine Cheng, Janice Yu, Cristina L. Abrahams, Xioafan Li, Jeff Hanson, Cuong Tran, Gang Yin, Shamim Ahmad, Krishna Bajjuri, Venita DeAlmeida, Mark Lupher, Trevor Hallam

Cancer Res (2020) 80 (16_Supplement): 2250.

https://doi.org/10.1158/1538-7445.AM2020-2250

Published: 15 August 2020

View article titled, Abstract 2250: STRO-002, an anti-FolRαADC, demonstrates immune-modulating properties and potentiates PD-L1 blockade

Journal Articles

Abstract 67: Characterization and preclinical development of STRO-001, a novel CD74-targeting antibody-drug conjugate (ADC) for the treatment of B-cell malignancies

Cristina Abrahams, Xiaofan Li, Venita DeAlmeida, Millicent Embry, Abigail Yu, Stellanie Krim, Heidi Hoffmann, James Zawada, Maureen Bruhns, Shannon Matheny, Stuart Bussell, Toni Kline, Alice Yam, Ryan Stafford, Trevor Hallam, Mark Lupher, Arturo Molina

Cancer Res (2017) 77 (13_Supplement): 67.

https://doi.org/10.1158/1538-7445.AM2017-67

Published: 01 July 2017

View article titled, Abstract 67: Characterization and preclinical development of STRO-001, a novel CD74-targeting antibody-drug conjugate (ADC) for the treatment of B-cell malignancies

Journal Articles

Abstract 1695: Development of a novel antibody-drug conjugate for the treatment of c-Kit expressing solid tumors and AML

Tinya J. Abrams, Xiaohong Niu, Millicent Embry, Janine Kline, Montesa Patawaran, Christie Fanton, Marjorie Ison-Dugenny, Tracy Schneider, Kathy Miller, Zhen Wang, Majid Ghoddusi, Steven Cohen, E. Erica Hong, Emma Lees, Siew Schleyer

Cancer Res (2015) 75 (15_Supplement): 1695.

https://doi.org/10.1158/1538-7445.AM2015-1695

Published: 01 August 2015

View article titled, Abstract 1695: Development of a novel antibody-drug conjugate for the treatment of c-Kit expressing solid tumors and AML

Journal Articles

Small molecule inhibitors of CHK1 cause abrogation of the G2/M cell cycle checkpoint in vitro and tumor regression in a murine xenograft model.

Barbara Hibner, Katherine Rendahl, Kim Aardalen, Millicent Embry, Yi Shao, Daniel Menezes, Sylvia Ma, Trina Slabiak, Tom Gesner

Cancer Res (2004) 64 (7_Supplement): 537.

Published: 01 April 2004

View article titled, Small molecule inhibitors of CHK1 cause abrogation of the G2/M cell cycle checkpoint in vitro and tumor regression in a murine xenograft model.

Journal Articles

CHIR 124, a novel and potent inhibitor of chk1, potentiates the anti-tumor activity of topoisomerase I poisons in vitro and in vivo.

Archie N. Tse, Millicent Embry, Kim Aardalen, Yi Shao, Katherine Rendahl, Daniel Menezes, Barbara Hibner, Tom Gesner, Gary Schwartz

Cancer Res (2004) 64 (7_Supplement): 537.

Published: 01 April 2004

View article titled, CHIR 124, a novel and potent inhibitor of chk1, potentiates the anti-tumor activity of topoisomerase I poisons in vitro and in vivo.

Journal Articles

Antitumor Synergy of CV787, a Prostate Cancer-specific Adenovirus, and Paclitaxel and Docetaxel

De-Chao Yu, Yu Chen, Jeanette Dilley, Yuanhao Li, Millicent Embry, Hong Zhang, Natalie Nguyen, Pinky Amin, Joe Oh, Daniel R. Henderson

Cancer Res (2001) 61 (2): 517–525.

Published: 01 January 2001

View article titled, Antitumor Synergy of CV787, a Prostate Cancer-specific Adenovirus, and Paclitaxel and Docetaxel

NARROW

Abstract 2250: STRO-002, an anti-FolRαADC, demonstrates immune-modulating properties and potentiates PD-L1 blockade

Abstract 67: Characterization and preclinical development of STRO-001, a novel CD74-targeting antibody-drug conjugate (ADC) for the treatment of B-cell malignancies

Abstract 1695: Development of a novel antibody-drug conjugate for the treatment of c-Kit expressing solid tumors and AML

Small molecule inhibitors of CHK1 cause abrogation of the G2/M cell cycle checkpoint in vitro and tumor regression in a murine xenograft model.

CHIR 124, a novel and potent inhibitor of chk1, potentiates the anti-tumor activity of topoisomerase I poisons in vitro and in vivo.

Antitumor Synergy of CV787, a Prostate Cancer-specific Adenovirus, and Paclitaxel and Docetaxel

Email alerts

AACR Journals

Abstract 2250: STRO-002, an anti-FolRαADC, demonstrates immune-modulating properties and potentiates PD-L1 blockade

Abstract 67: Characterization and preclinical development of STRO-001, a novel CD74-targeting antibody-drug conjugate (ADC) for the treatment of B-cell malignancies

Abstract 1695: Development of a novel antibody-drug conjugate for the treatment of c-Kit expressing solid tumors and AML

Small molecule inhibitors of CHK1 cause abrogation of the G2/M cell cycle checkpoint in vitro and tumor regression in a murine xenograft model.

CHIR 124, a novel and potent inhibitor of chk1, potentiates the anti-tumor activity of topoisomerase I poisons in vitro and in vivo.

Antitumor Synergy of CV787, a Prostate Cancer-specific Adenovirus, and Paclitaxel and Docetaxel

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only